French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry

• DOI: 10.1111/bjh.19505
• Publication Date: 2024-05-15T08:35:51Z
• Authors: B. Ferment; J. Lambert; D. Caillot; I. Lafon; L. Karlin; A. Lazareth; C. Touzeau; X. Leleu; N. Moya; S. Harel; A. Perrot; P. Bories; L. Vincent; S. Lamure; M. Mohty; F. Malard; S. Manier; I. Yakoub‐Agha; J.‐M. Schiano De ...; G. Brisou; A. Talbot; O. Decaux; R. Houot; S. Le Gouill; N. Bigot; T. Facon; J. Corre; P. Moreau; B. Arnulf
• Keywords: Cytokine Release Syndrome; Expanded access; Refractory (planetary science)

Idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T-cell therapy targeting B-cell maturation (BCMA), received early access program (EAP) authorization in France April 2021 for relapsed/refractory multiple myeloma (RRMM). We conducted real-world registry-based multicentre observational study 11 French hospitals to evaluate ide-cel outcomes. Data from 176 RRMM patients who underwent apheresis between June and November 2022 were collected the national DESCAR-T registry. Of these, 159 (90%) ide-cel. Cytokine release syndrome occurred 90% with 2% grade ≥3, neurotoxicity 12% 3% ≥3. Over first 6 months, best overall response ≥complete rates 88% 47% respectively. The median progression-free survival (PFS) infusion was 12.5 (OS) 20.8 months estimated OS rate at 12 73.3%. Patients extra-medullary disease (EMD) had impaired PFS (6.2 vs. 14.8 months). On multivariable analysis, EMD previous exposure BCMA-targeted immunoconjugate or T-cell-redirecting GPRC5D bispecific antibody associated inferior PFS. Our supports ide-cel's feasibility, safety efficacy real-life settings, emphasizing importance of screening considering prior treatments optimize patient selection.